Cortexyme, Inc. NASDAQ:CRTX

Founder-led company

Cortexyme stock price today

$1.95
Financial Health
0
1
2
3
4
5
6
7
8
9

Cortexyme stock price monthly change

-21.69%
month

Cortexyme stock price quarterly change

-40.55%
quarter

Cortexyme stock price yearly change

-98.03%
year

Cortexyme key metrics

Market Cap
70.45M
Enterprise value
N/A
P/E
-0.65
EV/Sales
N/A
EV/EBITDA
0.05
Price/Sales
N/A
Price/Book
0.55
PEG ratio
0.04
EPS
-4.47
Revenue
N/A
EBITDA
-149.26M
Income
-149.92M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cortexyme stock price history

Cortexyme stock forecast

Cortexyme financial statements

Cortexyme, Inc. (NASDAQ:CRTX): Profit margin
Sep 2021 0 -21.70M
Dec 2021 0 -89.94M
Mar 2022 0 -21.71M
Jun 2022 0 -16.56M
Cortexyme, Inc. (NASDAQ:CRTX): Earnings per share (EPS)
2022-03-01 -0.65 -0.78
Cortexyme, Inc. (NASDAQ:CRTX): Debt to assets
Sep 2021 147416000 14.76M 10.02%
Dec 2021 133228000 14.64M 10.99%
Mar 2022 116130000 9.75M 8.4%
Jun 2022 117863000 6.33M 5.37%
Cortexyme, Inc. (NASDAQ:CRTX): Cash Flow
Jun 2021 -17.56M 5.62M 672K
Sep 2021 -17.34M 766K 4.70M
Dec 2021 -14.41M 20.91M 990K
Mar 2022 -16.09M 13.41M 622K

Cortexyme alternative data

Cortexyme, Inc. (NASDAQ:CRTX): Employee count
Aug 2023 55
Sep 2023 55
Oct 2023 55
Nov 2023 55
Dec 2023 55
Jan 2024 55
Feb 2024 55
Mar 2024 55
Apr 2024 55
May 2024 55
Jun 2024 55
Jul 2024 55

Cortexyme other data

Cortexyme, Inc. (NASDAQ:CRTX): Insider trades (number of shares)
Period Buy Sel
Jul 2021 0 116522
Aug 2021 0 38000
Oct 2021 0 5963
Nov 2021 763 0
Jun 2022 0 10800
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MCDOWELL CARYN GORDON officer: Chief Le.. Common Stock 10,800 $2.86 $30,920
Option
LYNCH CASEY director, officer.. Stock Option (Right to Buy) 60,000 $0.46 $27,600
Option
LYNCH CASEY director, officer.. Common Stock 60,000 $0.46 $27,600
Option
LOWE CHRISTOPHER P. officer: COO & Chief Financial ..
Stock Option (right to buy) 30,000 $2.23 $66,900
Option
LOWE CHRISTOPHER P. officer: COO & Chief Financial ..
Common Stock 30,000 $2.23 $66,900
Purchase
DOMINY STEPHEN S. director, officer: Chief Scient..
Common Stock 763 $14.4 $10,987
Option
MCLOUGHLIN MARGARET director
Stock Option (right to buy) 1,000 $17 $17,000
Sale
MCLOUGHLIN MARGARET director
Common Stock 1,000 $88.93 $88,930
Option
MCLOUGHLIN MARGARET director
Common Stock 1,000 $17 $17,000
Option
LOWE CHRISTOPHER P. officer: COO & Chief Financial ..
Stock Option (Right to Buy) 4,963 $54.85 $272,221
Patent
Application
Filling date: 20 Mar 2020 Issue date: 30 Jun 2022
Grant
Filling date: 4 May 2020 Issue date: 17 May 2022
Grant
Filling date: 11 Jun 2020 Issue date: 10 May 2022
Application
Filling date: 27 Sep 2019 Issue date: 18 Nov 2021
Application
Filling date: 8 Jul 2021 Issue date: 4 Nov 2021
Grant
Filling date: 8 Nov 2019 Issue date: 13 Jul 2021
Application
Filling date: 11 Jun 2020 Issue date: 25 Feb 2021
Grant
Filling date: 9 May 2018 Issue date: 2 Feb 2021
Application
Filling date: 4 May 2020 Issue date: 21 Jan 2021
Grant
Filling date: 14 Mar 2019 Issue date: 4 Aug 2020
Tuesday, 15 March 2022
InvestorPlace
Tuesday, 8 March 2022
Benzinga
Monday, 28 February 2022
Seeking Alpha
Friday, 18 February 2022
Zacks Investment Research
Wednesday, 2 February 2022
Zacks Investment Research
Tuesday, 1 February 2022
InvestorPlace
Wednesday, 26 January 2022
Schaeffers Research
Benzinga
Wednesday, 12 January 2022
The Motley Fool
Friday, 7 January 2022
InvestorPlace
Friday, 17 December 2021
InvestorPlace
Wednesday, 15 December 2021
Seeking Alpha
Monday, 6 December 2021
Benzinga
Wednesday, 1 December 2021
Zacks Investment Research
Wednesday, 17 November 2021
Seeking Alpha
Thursday, 11 November 2021
Benzinga
Friday, 5 November 2021
Seeking Alpha
Wednesday, 3 November 2021
Benzinga
Thursday, 28 October 2021
The Motley Fool
The Motley Fool
Wednesday, 27 October 2021
InvestorPlace
Benzinga
The Motley Fool
Market Watch
Tuesday, 26 October 2021
Benzinga
Saturday, 16 October 2021
Seeking Alpha
Monday, 11 October 2021
Seeking Alpha
Sunday, 12 September 2021
Seeking Alpha
Monday, 16 August 2021
Benzinga
  • What's the price of Cortexyme stock today?

    One share of Cortexyme stock can currently be purchased for approximately $1.95.

  • When is Cortexyme's next earnings date?

    Unfortunately, Cortexyme's (CRTX) next earnings date is currently unknown.

  • Does Cortexyme pay dividends?

    No, Cortexyme does not pay dividends.

  • How much money does Cortexyme make?

    Cortexyme has a market capitalization of 70.45M. Cortexyme made a loss 89.95M US dollars in net income (profit) last year or -$0.78 on an earnings per share basis.

  • What is Cortexyme's stock symbol?

    Cortexyme, Inc. is traded on the NASDAQ under the ticker symbol "CRTX".

  • What is Cortexyme's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cortexyme?

    Shares of Cortexyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cortexyme's key executives?

    Cortexyme's management team includes the following people:

    • Ms. Casey C. Lynch Co-Founder, Chairman, Pres & Chief Executive Officer(age: 51, pay: $787,500)
    • Dr. Michael J. Detke M.D., Ph.D. Chief Medical Officer(age: 58, pay: $574,000)
    • Dr. Leslie J. Holsinger Ph.D. Executive Vice President of R&D(age: 60, pay: $567,000)
    • Mr. Christopher P. Lowe M.B.A. Chief Operating Officer, Chief Financial Officer & Treasurer(age: 54, pay: $546,000)
    • Ms. Caryn Gordon McDowell Chief Legal & Admin. Officer and Corporation Sec.(age: 55, pay: $513,160)
  • Is Cortexyme founder-led company?

    Yes, Cortexyme is a company led by its founder Ms. Casey C. Lynch.

  • How many employees does Cortexyme have?

    As Jul 2024, Cortexyme employs 55 workers.

  • When Cortexyme went public?

    Cortexyme, Inc. is publicly traded company for more then 6 years since IPO on 9 May 2019.

  • What is Cortexyme's official website?

    The official website for Cortexyme is cortexyme.com.

  • Where are Cortexyme's headquarters?

    Cortexyme is headquartered at 269 E Grand Ave, South San Francisco, CALIFORNIA.

  • How can i contact Cortexyme?

    Cortexyme's mailing address is 269 E Grand Ave, South San Francisco, CALIFORNIA and company can be reached via phone at +1 415 910 5717.

Cortexyme company profile:

Cortexyme, Inc.

cortexyme.com
Exchange:

NASDAQ

Full time employees:

55

Industry:

Biotechnology

Sector:

Healthcare

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

269 E Grand Ave
South San Francisco, CALIFORNIA 94080

CIK: 0001662774
ISIN: US22053A1079
CUSIP: 22053A107